Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Publication Type:

Journal Article

Source:

The Prostate, Volume 68, Issue 10, p.1105-15 (2008)

Keywords:

2008, androgens, Animals, Antibiotics, Antineoplastic, Cell Division, Clinical Research Division, Disease Models, Animal, Doxorubicin, Drug Therapy, Combination, Male, MICE, Mice, Inbred C57BL, Mice, Transgenic, Neovascularization, Pathologic, Prostatic Neoplasms, Receptors, Androgen, Tumor Necrosis Factor-alpha

Abstract:

Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-alpha derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC.